These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 33588308)

  • 1. Innate myeloid cells in the tumor microenvironment.
    Duhan V; Smyth MJ
    Curr Opin Immunol; 2021 Apr; 69():18-28. PubMed ID: 33588308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment.
    Carnevalli LS; Ghadially H; Barry ST
    Front Immunol; 2021; 12():633685. PubMed ID: 33953710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies.
    Liu Y; Guo J; Huang L
    Theranostics; 2020; 10(7):3099-3117. PubMed ID: 32194857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innate immune cells in the tumor microenvironment.
    Li MO; Wolf N; Raulet DH; Akkari L; Pittet MJ; Rodriguez PC; Kaplan RN; Munitz A; Zhang Z; Cheng S; Bhardwaj N
    Cancer Cell; 2021 Jun; 39(6):725-729. PubMed ID: 34129817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.
    Fleming V; Hu X; Weber R; Nagibin V; Groth C; Altevogt P; Utikal J; Umansky V
    Front Immunol; 2018; 9():398. PubMed ID: 29552012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
    Kamran N; Chandran M; Lowenstein PR; Castro MG
    Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Innate Immunity in Breast Cancer Therapy: A Narrative Review.
    Ye Y; Xu C; Chen F; Liu Q; Cheng N
    Front Immunol; 2021; 12():771201. PubMed ID: 34899721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses.
    Hossain F; Majumder S; Ucar DA; Rodriguez PC; Golde TE; Minter LM; Osborne BA; Miele L
    Front Immunol; 2018; 9():1288. PubMed ID: 29915603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
    Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
    Front Immunol; 2020; 11():784. PubMed ID: 32457745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives.
    Mortezaee K
    Life Sci; 2021 Jul; 277():119627. PubMed ID: 34004256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the myeloid microenvironment in neuroblastoma.
    Stip MC; Teeuwen L; Dierselhuis MP; Leusen JHW; Krijgsman D
    J Exp Clin Cancer Res; 2023 Dec; 42(1):337. PubMed ID: 38087370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy.
    Krishnamoorthy M; Gerhardt L; Maleki Vareki S
    Cells; 2021 May; 10(5):. PubMed ID: 34065010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
    De Cicco P; Ercolano G; Ianaro A
    Front Immunol; 2020; 11():1680. PubMed ID: 32849585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type I interferon-mediated tumor immunity and its role in immunotherapy.
    Yu R; Zhu B; Chen D
    Cell Mol Life Sci; 2022 Mar; 79(3):191. PubMed ID: 35292881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of the tumor immune microenvironment by the Hippo Pathway: Implications for cancer immunotherapy.
    Liu C; Song Y; Li D; Wang B
    Int Immunopharmacol; 2023 Sep; 122():110586. PubMed ID: 37393838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Immune Microenvironment and Its Related miRNAs in Tumor Progression.
    Xing Y; Ruan G; Ni H; Qin H; Chen S; Gu X; Shang J; Zhou Y; Tao X; Zheng L
    Front Immunol; 2021; 12():624725. PubMed ID: 34084160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting myeloid-derived suppressive cells in the tumor microenvironment to enhance the efficacy of cancer immunotherapy.
    Huo S; Liu L; Li Q; Wang J
    Discov Med; 2020; 30(161):119-128. PubMed ID: 33593480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy.
    Clappaert EJ; Murgaski A; Van Damme H; Kiss M; Laoui D
    Front Immunol; 2018; 9():2250. PubMed ID: 30349530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment.
    Nakamura K; Smyth MJ
    Cell Mol Immunol; 2020 Jan; 17(1):1-12. PubMed ID: 31611651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasticity in Pro- and Anti-tumor Activity of Neutrophils: Shifting the Balance.
    Furumaya C; Martinez-Sanz P; Bouti P; Kuijpers TW; Matlung HL
    Front Immunol; 2020; 11():2100. PubMed ID: 32983165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.